Danone’s $12.5 billion purchase of WhiteWave, a soy and almond milk maker based in the United States, is an expensive way of buying growth. The French dairy group can get away with it because expanding outside of Europe looks attractive, and debt comes cheap.
The maker of Activia yoghurt, which a decade ago was deemed by France too precious to be taken over by foreigners, will pay almost 20 times WhiteWave’s forecast EBITDA. That in itself is not outlandish, since the U.S. group is growing rapidly, its sales increasing at twice the rate of Danone’s. The trouble is that WhiteWave, whose shareholders include activist Hudson Executive Capital according to Eikon data, is already trading at a full-fat valuation of 31 times the next 12 months’ estimated earnings.
Assume the company can sustain a growth rate in its operating profit of 12 percent each year from now until 2020, which is when Danone expects the synergies will come through. Add the resulting $666 million of operating profit to the $300 million of value Danone hopes to create from the deal, tax it at WhiteWave’s rate of 35 percent, and the return for investors is just 5 percent, below the target’s likely cost of capital.
That may seem at odds with Danone investors’ initially positive response, pushing up the shares more than 5 percent after the deal was announced. But that may rest on other factors, like the fact Europe may be about to take a big hit from the UK’s decision to leave the European Union, and WhiteWave doubles the percentage of Danone’s sales that comes from the United States.
Funding the deal entirely with debt also has appeal, since expectations of future interest rates are falling, judging by the narrowing gap between short and long-term U.S. government bond yields. But Danone could simply gear itself up, without paying full whack for a rival.
WhiteWave shareholders, meanwhile, get the cream. An agreed deal with Danone may even smoke out a rival bid from a U.S. food producer covetous of the rapid growth of supposedly healthier alternatives to milk. In that sense, the activists at Hudson have done a good job. Maybe as their next project, they should buy a stake in Danone.
By John Foley
Cécile Béliot has assumed the role of Bel Group chief executive officer, following the decision to separate the roles of chairman and CEO. The separation of the functions will enable Bel Group to develop in three areas of healthy snacking. Meanwhile, the company’s former CEO, Antoine Fiévet, has had his mandate renewed as chairman of the board.
US Food and Drug Administration (FDA) Commissioner Dr. Robert Califf was grilled by lawmakers during a House Appropriations subcommittee hearing, where he was slammed over the agency’s handling of the escalating infant formula shortage.
Sweegen is ramping up its efforts to reduce sugar across F&B applications while simultaneously tapping into the benefits of using antioxidants and bitter blocking technology. Speaking to FoodIngredientsFirst, Casey McCormick, vice president of global innovation at Sweegen, says product developers can find a broad range of solutions in Sweegen’s nature-based sweetener systems as brands elevate better-for-you foods.